Want to see CMMB full AI Analyst Report?
Top Page
Chemomab Therapeutics
(NASDAQ:CMMB)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.50
▲(8.70% Upside)
Action:Reiterated
Date:08/27/26
The score is held back primarily by weak financial performance (pre-revenue, persistent losses, and negative free cash flow implying ongoing financing/dilution risk), partially offset by a strong technical uptrend. Valuation remains constrained by negative earnings and the absence of a dividend yield in the provided data.
Positive Factors
Low Balance-Sheet Leverage
Minimal debt lowers solvency risk and preserves financial flexibility while Chemomab advances clinical programs. This provides a stronger base for future financing or partnering than a similarly loss-making biotech carrying significant liabilities.
Negative Factors
Pre-Revenue Business Model
Without product revenue, the company has no recurring commercial cash inflow to fund research, trials or corporate expenses. Its fundamental value therefore remains dependent on clinical progress, regulatory success and eventual partnering or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Balance-Sheet Leverage
Minimal debt lowers solvency risk and preserves financial flexibility while Chemomab advances clinical programs. This provides a stronger base for future financing or partnering than a similarly loss-making biotech carrying significant liabilities.
Read all positive factors
Chemomab Therapeutics (CMMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.66M
Dividend YieldN/A
Average Volume (3M)207.96K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS Growth56.99%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,200,378
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Chemomab Therapeutics Business Overview & Revenue Model
Company Description
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclona...
How the Company Makes Money
Chemomab is a clinical-stage biotech and, as such, it has historically not been primarily a product-revenue company; its operations are generally funded through external financing and, where applicable, collaboration-related proceeds. Potential an...
Chemomab Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -66.83K | -57.77K | -34.02K |
| EBITDA | -7.88M | -9.50M | -14.69M | -25.39M | -28.48M | -12.34M |
| Net Income | -7.46M | -8.99M | -13.95M | -24.22M | -27.65M | -12.49M |
Balance Sheet | ||||||
| Total Assets | 11.81M | 13.81M | 16.96M | 22.15M | 43.06M | 64.35M |
| Cash, Cash Equivalents and Short-Term Investments | 8.04M | 10.37M | 14.27M | 19.78M | 39.89M | 61.16M |
| Total Debt | 0.00 | 0.00 | 324.00K | 392.00K | 214.00K | 343.00K |
| Total Liabilities | 1.11M | 1.48M | 3.43M | 5.15M | 6.84M | 2.89M |
| Stockholders Equity | 10.70M | 12.33M | 13.54M | 17.00M | 36.22M | 61.47M |
Cash Flow | ||||||
| Free Cash Flow | -11.22M | -11.22M | -15.46M | -23.55M | -20.36M | -12.62M |
| Operating Cash Flow | -11.22M | -11.22M | -15.46M | -23.55M | -20.29M | -12.38M |
| Investing Cash Flow | 5.43M | 5.43M | 2.31M | 15.84M | 19.46M | -45.22M |
| Financing Cash Flow | 7.21M | 7.21M | 9.91M | 3.49M | -804.84K | 61.12M |
Chemomab Therapeutics Technical Analysis
Positive
2.30
Price Trends
1.76
Positive
1.74
Positive
1.84
Positive
Market Momentum
0.17
Negative
82.03
Negative
85.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMMB, the sentiment is Positive. The current price of 2.3 is above the 20-day moving average (MA) of 1.93, above the 50-day MA of 1.76, and above the 200-day MA of 1.84, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 82.03 is Negative, neither overbought nor oversold. The STOCH value of 85.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CMMB.
Chemomab Therapeutics Risk Analysis
Chemomab Therapeutics disclosed 60 risk factors in its most recent earnings report. Chemomab Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Chemomab Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $485.84M | 5.80 | 76.88% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $16.66M | -2.53 | -67.85% | ― | ― | 56.99% | |
45 Neutral | $21.68M | -0.70 | -202.41% | ― | -42.74% | 20.65% | |
44 Neutral | $20.08M | -0.43 | 4092.98% | ― | ― | 15.37% | |
42 Neutral | $86.82M | -1.42 | -61.55% | ― | ― | -59.74% | |
32 Underperform | $15.54M | -0.40 | -150.88% | ― | ― | 38.14% |
* Healthcare Sector Average
CMMB
Chemomab Therapeutics
2.59
-0.89
-25.57%
TENX
Tenax Therapeutics
2.12
-3.80
-64.19%
QTTB
Q32 Bio
16.18
14.46
840.70%
PASG
Passage Bio
4.50
-2.54
-36.08%
CALC
CalciMedica
0.59
-2.31
-79.76%
LGVN
Longeveron
0.70
-0.12
-14.37%
Chemomab Therapeutics Corporate Events
Chemomab Therapeutics Files Q2 2026 Results and Updates SEC Registrations
Aug 19, 2026
On August 19, 2026, Chemomab Therapeutics filed a Form 6‑K with the U.S. Securities and Exchange Commission, reporting unaudited condensed consolidated financial results for the three‑ and six‑month periods ended June 30, 2026. T...
Chemomab Therapeutics and Scipher Medicine to Merge in AI‑Driven Rheumatoid Arthritis Play
Jul 8, 2026
On July 7–8, 2026, Chemomab Therapeutics and Scipher Medicine entered into a definitive stock‑for‑stock merger agreement that will redomicile Chemomab to the U.S. and combine Scipher as a wholly owned subsidiary under a new paren...
Chemomab Therapeutics Revamps Board and Committees With New Independent Director
Jun 2, 2026
On June 1, 2026, Chemomab Therapeutics’ board appointed veteran biotech dealmaker Gwen Melincoff as a Class I director and chair of the nominating and governance committee, expanding the board to five members and adding extensive business de...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.